<p>The treatment of hepatocellular carcinoma (HCC) is a worldwide urgent and pressing challenge. Magnetic hyperthermia therapy (MHT) is a relatively new therapeutic strategy for tumors in resent years, especially magnesium (Mg) implants with eddy thermal effect can be employed for MHT to therapy tumor. PANoptosis is a new type of programmed cell death (PCD), driven by Caspases and RIPKs through the formation of PANoptosomes. In our early study, we discovered Zn<sup>2+</sup> came from Zn-LDH@Mg implant could induce pyroptosis. In this work, we further demonstrate that Zn<sup>2+</sup> comes from Zn-LDH@Mg implant can induce PANoptosis-like cell death in MHT to therapy H22 cells and tumors, verified by immunofluorescence staining, TUNEL staining, western blot assay, ELISA and transcriptomics analysis. This work is the first time to combine MHT and PANoptosis to therapy HCC, emphasizing the importance of materials design for MHT, and providing a useful foundation for materials design combined with PCD to treat tumors.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Zinc ions trigger PANoptosis-like cell death in magnetic hyperthermia therapy of magnesium based implant for hepatocellular carcinoma

  • Anhong Liu,
  • Xiao Han,
  • Qianqian Yang,
  • Xiangxue Meng,
  • Hao Qiu,
  • Chunjie Wu,
  • Xiaoming Li,
  • Mengmeng Cai,
  • Tinghe Duan,
  • Zhanhui Wang

摘要

The treatment of hepatocellular carcinoma (HCC) is a worldwide urgent and pressing challenge. Magnetic hyperthermia therapy (MHT) is a relatively new therapeutic strategy for tumors in resent years, especially magnesium (Mg) implants with eddy thermal effect can be employed for MHT to therapy tumor. PANoptosis is a new type of programmed cell death (PCD), driven by Caspases and RIPKs through the formation of PANoptosomes. In our early study, we discovered Zn2+ came from Zn-LDH@Mg implant could induce pyroptosis. In this work, we further demonstrate that Zn2+ comes from Zn-LDH@Mg implant can induce PANoptosis-like cell death in MHT to therapy H22 cells and tumors, verified by immunofluorescence staining, TUNEL staining, western blot assay, ELISA and transcriptomics analysis. This work is the first time to combine MHT and PANoptosis to therapy HCC, emphasizing the importance of materials design for MHT, and providing a useful foundation for materials design combined with PCD to treat tumors.